Search results
Results from the WOW.Com Content Network
Ovarian remnant syndrome[1] is a condition that occurs when ovarian tissue is left behind following oophorectomy, causing development of a pelvic mass, pelvic pain, and occasionally dyspareunia. [2] Ovarian remnant syndrome (ORS) is characterized by the presence of residual ovarian tissue after a woman has had surgery to remove one ovary or ...
The risk of ovarian cancer increases with age. Most cases of ovarian cancer develop after menopause. [16] It is also more common in women who have ovulated more over their lifetime. [17] This includes those who have never had children, those who began ovulation at a younger age and those who reach menopause at an older age. [5]
High-grade serous carcinoma (HGSC) is a type of tumour that arises from the serous epithelial layer in the abdominopelvic cavity and is mainly found in the ovary. HGSCs make up the majority of ovarian cancer cases [1] and have the lowest survival rates. [2] HGSC is distinct from low-grade serous carcinoma (LGSC) which arises from ovarian tissue ...
Ovarian tumor. Gross pathology of an ovarian carcinoma. Ovarian tumors, or ovarian neoplasms, are tumors found in the ovary. They can be benign or malignant (ovarian cancer). They consist of mainly solid tissue, while ovarian cysts contain fluid.
Kristina Coccoluto, 38, has spent her life watching the women in her family be diagnosed with cancer. One aunt was diagnosed with breast cancer when Coccoluto was 7 and died of breast and ovarian ...
Hormone replacement therapy. Hormone replacement therapy (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is a form of hormone therapy used to treat symptoms associated with female menopause. [1][2] Effects of menopause can include symptoms such as hot flashes, accelerated skin aging, vaginal dryness, decreased ...
The event is held each September during Ovarian Cancer Awareness Month. Now in its 11th year, the Chic Awearness event is closing in on $1 million raised for awareness, patient support and ...
Borderline ovarian tumours (BOTs) have been qualified as low malignant potential tumours by the FIGO since 1971. They are classified within malignant epithelial ovarian tumours, constituting 10–20% of these. [4] Their incidence is low, and is calculated in European series at around 4.8/100,000 new cases per year and even lower in American ...